// Biotech and Pharma Therapeutics
J&J puts focus on cancer drugs in push to reach 2025 sales target
January 24, 2023 / J&J / Cancer Drugs / Drugmaker
Bristol Myers CMO, others still skeptical about cancer vaccines as BioNTech, Moderna march ahead with I-O partners
January 25, 2023 / JPM 2023 / Cancer Vaccine / Immuno-oncology / mRNA
J&J trims the edges of its pipeline with the company mum on timing of looming readouts
January 24, 2023 / Johnson & Johnson / Prostate Cancer / Milvexian / Carvykti
JPM23: Pfizer, Moderna and more look to combine COVID and flu vaccine markets
January 23, 2022 / JPM 2023 / Moderna / Pfizer / GSK
Astellas Plots Near-Term Moves to Execute Long-Term Vision in Gene Therapy
January 24, 2023 / Astellas / Gene Therapy
// 4th Industrial Revolution
Why Patient Portal Usability is Critical to Patient Experience
January 25, 2023 / Patient Experience / Healthcare
Bay Area biotech uses AI to unlock RNA structures — and find new therapies in the process
January 25, 2023 / Bay Area / AI / Healthcare / New Therapies
Nvidia’s AI Tech Designs Proteins Never Seen in Nature, Pointing Way to New Therapies
Engineering techniques are already used to design novel proteins with the potential to become new therapies. Nvidia and partner Evozyne have new research showing that their technologies created novel proteins never before seen in nature, doing it faster and with better results. They did it by studying the language of life.
Technology could improve pregnancy care for low-income patients — if health systems can pay for it
First-in-human implants for Amber Therapeutics’ bioelectrical therapy
// Business & Markets
Is Amazon’s RxPass Breaking New Ground in Creating Access to Affordable Drugs?
January 24, 2023 / Amazon / Affordable Drugs / RxPass
Lilly to boost diabetes drug production with $450M factory investment
January 24, 2023 / Eli Lilly / Novo Nordisk / Investment / Diabetes
Eli Lilly will invest $450 million in a North Carolina manufacturing plant to meet growing demand for its diabetes drugs Mounjaro and Trulicity, the company said Tuesday. The investment in the Research Triangle Park plant will expand filling, device assembly and packaging capacity to help the Indiana-based drugmaker double production of the injectable drugs by the end of 2023.
Behind the deal: AstraZeneca’s eagerness for CinCor acquisition revealed in larger initial offer
January 24, 2023 / AstraZeneca / CinCor Pharma / M&A
Bayer’s oncology business looks to collect $10B in sales by 2030, exec says
Jaunary 24 2023 / Bayer / Christine Roth / Nubeqa
How a buyer’s sudden withdrawal gave Ipsen a chance to fight for Albireo
January 24, 2023 / M&A / Ipsen / Rare Diseases / Albireo
// Legal & Regulatory
Lilly turns to nonprofit, not the FDA, to resolve dispute with Novartis over a prescription drug ad
January 25, 2023 / Eli Lilly / FDA / Prescription Drug Ad / Novartis
In a rare move, the BBB National Programs settled a dispute between two big drug companies over a prescription drug ad, suggesting the nonprofit may take a larger role in resolving complaints that might normally be handled by the U.S. Food and Drug Administration. The Dispute began when Eli Lilly challenged some of the information in an ad that Noovartis had run for its Kisqali breast cancer treatment.